Published in:

01-09-1997 | Original Article

A 2-Year Phase II Study with 1-Year of Follow-up of Risedronate (NE-58095) in Postmenopausal Osteoporosis

Authors: B. Clemmesen, P. Ravn, B. Zegels, A.N. Taquet, C. Christiansen, J.Y. Reginster

Published in: Osteoporosis International | Issue 5/1997